Understanding daytime functioning in insomnia: responder and correlation analyses in patients treated with daridorexant

Table 1 Baseline demographic and insomnia characteristics in the overall study group

Characteristics	All patients N = 930
Sex, n (%)
Female	624 (67%)
Male	306 (33%)
Age at screening, years, mean (SD)	55.4 (15.3)
Age group, years, n (%)
≥ 65	364 (39%)
< 65	566 (61%)
Race, n (%)
White	839 (90%)
Black / African American	77 (8%)
Asian	9 (1%)
Other	5 (1%)
Geographical location, n (%)
Europe	617 (66%)
USA	300 (32%)
Canada	13 (1%)
BMI, kg/m², mean (SD)	26.4 (4.3)
BMI > 30 kg/m², n (%)	175 (19%)
Time since insomnia diagnosis, years, mean (SD)	10.6 (10.4)
Nighttime variables, mean (SD)
WASO, min^a	98.6 (39.2)
LPS, min^a	65.8 (38.6)
Total sleep time, min^a	323.1 (53.4)
Self-reported total sleep time, min	313 (57.0)
Insomnia severity index score, mean (SD) (0–28)^b	19.1 (4.1)
IDSIQ total score, mean (SD) (0–140)^c	73.7 (24.8)
VAS quality of sleep, mean (SD) (0–100)^d	35.8 (17.5)
VAS morning sleepiness, mean (SD) (0–100)^d	37.5 (18.8)

BMI body mass index, IDSIQ Insomnia Daytime Symptoms and Impacts Questionnaire, LPS latency to persistent sleep, SD standard deviation, VAS visual analog scale, WASO wake time after sleep onset
^aPolysomnography values, mean of two consecutive nights
^bhigher insomnia severity index score indicates more severe insomnia
^clower IDSIQ total score indicates better daytime functioning
^dhigher VAS scores indicate better quality of sleep and less morning sleepiness

ISSN: 2398-2683